Scholar Rock Holding Corp (SRRK)
27.05
-0.45
(-1.64%)
USD |
NASDAQ |
Nov 15, 12:16
Scholar Rock Cash from Investing (Quarterly): 50.62M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 50.62M |
March 31, 2024 | 33.38M |
December 31, 2023 | -25.13M |
September 30, 2023 | -8.473M |
June 30, 2023 | -15.24M |
March 31, 2023 | 89.98M |
December 31, 2022 | 0.077M |
September 30, 2022 | -145.72M |
June 30, 2022 | 44.52M |
March 31, 2022 | -70.58M |
December 31, 2021 | 29.46M |
September 30, 2021 | 3.283M |
June 30, 2021 | 79.02M |
March 31, 2021 | 22.56M |
December 31, 2020 | -122.64M |
Date | Value |
---|---|
September 30, 2020 | -35.87M |
June 30, 2020 | 38.93M |
March 31, 2020 | 56.09M |
December 31, 2019 | 21.21M |
September 30, 2019 | -72.17M |
June 30, 2019 | 21.10M |
March 31, 2019 | -32.38M |
December 31, 2018 | -60.94M |
September 30, 2018 | -0.598M |
June 30, 2018 | 24.89M |
March 31, 2018 | -23.59M |
December 31, 2017 | 5.898M |
September 30, 2017 | 8.975M |
June 30, 2017 | 1.424M |
March 31, 2017 | 1.368M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-145.72M
Minimum
Sep 2022
89.98M
Maximum
Mar 2023
2.393M
Average
21.21M
Median
Dec 2019
Cash from Investing (Quarterly) Benchmarks
Cytokinetics Inc | -45.05M |
Regeneron Pharmaceuticals Inc | -574.40M |
Ocugen Inc | -0.513M |
Mirum Pharmaceuticals Inc | -72.72M |
NeuroBo Pharmaceuticals Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -49.20M |
Cash from Financing (Quarterly) | -0.033M |
Free Cash Flow | -168.65M |
Free Cash Flow Per Share (Quarterly) | -0.5084 |
Free Cash Flow Yield | -6.81% |